Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5
Dawson, J. R. D.; Wadman, G. M.; Zhang, P.; Gu, S.; Shroka, T.; Borrega-Roman, L.; Salanga, C.; Handel, T. M.; Kufareva, I.
Show abstract
By driving monocyte chemotaxis, the chemokine receptor CCR2 shapes inflammatory responses and the formation of tumor microenvironments. This makes it a promising target in inflammation and immuno-oncology; however, despite extensive efforts, there are no FDA-approved CCR2-targeting therapeutics. Cited challenges include the redundancy of the chemokine system, suboptimal properties of compound candidates, and species differences that confound the translation of results from animals to humans. Structure-based drug design can rationalize and accelerate the discovery and optimization of CCR2 antagonists to address these challenges. The prerequisites for such efforts include an atomic-level understanding of the molecular determinants of action of existing antagonists. In this study, using molecular docking and artificial-intelligence-powered compound library screening, we uncover the structural principles of small molecule antagonism and selectivity towards CCR2 and its sister receptor CCR5. CCR2 orthosteric inhibitors are shown to universally occupy an inactive-state-specific tunnel between receptor helices 1 and 7; we also discover an unexpected role for an extra-helical groove accessible through this tunnel, suggesting its potential as a new targetable interface for CCR2 and CCR5 modulation. By contrast, only shape complementarity and limited helix 8 hydrogen bonding govern the binding of various chemotypes of allosteric antagonists. CCR2 residues S1012.63 and V2446.36 are implicated as determinants of CCR2/CCR5 and human/mouse orthosteric and allosteric antagonist selectivity, respectively, and the role of S1012.63 is corroborated through experimental gain-of-function mutagenesis. We establish a critical role of induced fit in antagonist recognition, reveal strong chemotype selectivity of existing structures, and demonstrate the high predictive potential of a new deep-learning-based compound scoring function. Finally, this study expands the available CCR2 structural landscape with computationally generated chemotype-specific models well-suited for structure-based antagonist design.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 Macrodomain of SARS-CoV-2 96%
- Machine learning classification can reduce false positives in structure-based virtual screening 96%
- Turning high-throughput structural biology into predictive inhibitor design 94%
Similar papers in this journal
- Structure-based Evolution of G protein-biased μ-opioid Receptor Agonists 96%
- Chemical validation of Mycobacterium tuberculosis phosphopantetheine adenylyltransferase using fragment linking and CRISPR interference 93%
- Machine learning-augmented molecular dynamics simulations (MD) reveal insights into the disconnect between affinity and activation of ZTPriboswitch ligands 92%
Similar papers in this journal
- Expanding Automated Multiconformer Ligand Modeling to Macrocycles and Fragments 94%
- CryoEM reveals unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors 94%
- An unconventional gatekeeper mutation sensitizes inositol hexakisphosphate kinases to an allosteric inhibitor 94%
Similar papers in this journal
- Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking 95%
- Structural basis for the ligand recognition and signaling of free fatty acid receptors 93%
- Type-II kinase inhibitors that target Parkinson's Disease-associated LRRK2 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.